← Search & browse all drugs
ALIMENTARY TRACT AND METABOLISM › ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS › INTESTINAL ANTIINFECTIVES › Antibiotics
rifaximin
A07AA11
Forms & Strengths
- Oral tablets: 200 mg
- Oral tablets: 550 mg
Adult Dosing
- Traveler's diarrhea: 200 mg orally 3 times daily for 3 days
- Hepatic encephalopathy reduction in recurrence: 550 mg orally 2 times daily
- Irritable bowel syndrome with diarrhea (IBS-D): 550 mg orally 3 times daily for 14 days
Pediatric Dosing
- Traveler's diarrhea (children >= 12 years): 200 mg orally 3 times daily for 3 days
- Hepatic encephalopathy: Safety and efficacy not established in pediatric patients
- IBS-D: Safety and efficacy not established in pediatric patients
Indications
- Treatment of traveler's diarrhea caused by noninvasive strains of Escherichia coli in patients >= 12 years
- Reduction in risk of overt hepatic encephalopathy recurrence in adults
- Treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults
Mechanism of Action
- Semisynthetic, non-systemic antibiotic derived from rifamycin
- Binds to the beta-subunit of bacterial DNA-dependent RNA polymerase
- Inhibits bacterial RNA synthesis, leading to reduced gut bacterial load
Contraindications
- Hypersensitivity to rifaximin, any of the rifamycin antimicrobial agents, or any component of the formulation
- History of hypersensitivity reactions to the drug
Adverse Reactions
- Peripheral edema
- Nausea
- Dizziness
- Fatigue
- Ascites
- Pruritus
- Clostridioides difficile-associated diarrhea
Drug Interactions
- P-glycoprotein (P-gp) inhibitors (e.g., cyclosporine) may significantly increase systemic exposure
- CYP3A4 inducers/inhibitors have minimal clinical impact due to negligible systemic absorption
- May decrease the systemic efficacy of live attenuated bacterial vaccines (e.g., typhoid vaccine)
Curated Content: Needs Vetting Before Put to Clinical Use